Anterior chamber factors identified for OAG

Article

Anterior chamber depth (ACD) and anterior chamber angle (ACA) were the factors identified relating to the progression of open-angle glaucoma (OAG).

Anterior chamber depth (ACD) and anterior chamber angle (ACA) were the factors identified relating to the progression of open-angle glaucoma (OAG).

A group led by Dr Zhiying Pan, Department of Ophthalmology, Interdisciplinary School of Medicine and Engineering, University of Yamanashi, Chuo Yamanashi, Japan, included 157 glaucoma patients and 26 pseudophakic eye patients used as controls in the analysis.

The team used a scanning peripheral ACD analyzer to assess ACD by numeric grades ACDG 1 to 12 and ACA twice during 2003 and 2008. The exclusion criteria was history of laser or incisional surgery, other ocular diseases that may affect visual field, visual acuity less than 20/30 and treatment with pilocarpine ophthalmic solution.

ACDG and ACA reduced from 7.2±2.3 to 6.5±2.1 and 34.2±12.6 to 28.1±10.3, respectively in the glaucoma patients, but there were no significant changes observed in patients who underwent cataract surgery.

ACD changes were greater at the peripheral region than at the central region and the reduction in ACDG was strongly linked to deep initial ACDG and wide ACA. Rapid visual field deterioration was found in patients that had a shallow ACDG and narrow ACA.

Overall, ACDG and ACA declined with age and initial ACDG and ACA was linked to OAG progression over time.The paper for this study can be found in the Journal of Glaucoma.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.